糖尿病周围神经病变治疗研究进展
摘要
率随糖尿病病程的延长而显著升高。DPN不仅导致患者出现感觉异常、疼痛及肌无力，严重者可引发足部溃疡甚至
截肢，是糖尿病致残的主要原因之一。尽管其发病机制尚未完全阐明，但目前普遍认为高血糖引起的代谢紊乱、氧
化应激、微血管损伤及神经营养因子缺乏是核心病理环节。本文系统综述了DPN在血糖管理、代谢干预、抗氧化应
激、微循环改善及神经修复等方面的治疗研究进展，旨在为临床规范化诊疗提供参考。
关键词
全文:
PDF参考
[1]Saeedi P, Petersohn I, Salpea P, et al. Global andstimulated RAW264.7 cells [J]. Allergol Immunopathol
(Madr), 2021, 49(5): 1-8.
[19]Bernardoni BL, D’Agostino I, Scianò F, et al. The
challenging inhibition of Aldose Reductase for the treatment
of diabetic complications: a 2019-2023 update of the patent
literature [J]. Expert Opin Ther Pat, 2024, 34(11): 1085-103.
[20]Song L, Ye J, Cheng Q. Therapeutic effects
of mecobalamin combined with epalrestat on diabetic
peripheral neuropathy: reduction of inflammatory factors and
improvement in electromyogram indices [J]. Am J Transl Res,
2025, 17(4): 2898-906.
[21]Østergaard L, Finnerup NB, Terkelsen AJ, et al.
The effects of capillary dysfunction on oxygen and glucose
extraction in diabetic neuropathy [J]. Diabetologia, 2015,
58(4): 666-77.
[22]Wu JD, Tao S, Jin X, et al. PGE1 improves diabetic
peripheral neuropathy in patients with type 2 diabetes [J].
Prostaglandins Other Lipid Mediat, 2016, 126: 24-8.
[23]Jiang DQ, Li MX, Ma YJ, et al. Efficacy and safety
of prostaglandin E1 plus lipoic acid combination therapy
versus monotherapy for patients with diabetic peripheral
neuropathy [J]. J Clin Neurosci, 2016, 27: 8-16.
[24]Didangelos T, Tziomalos K, Margaritidis C, et al.
Efficacy of Administration of an Angiotensin Converting
Enzyme Inhibitor for Two Years on Autonomic and
Peripheral Neuropathy in Patients with Diabetes Mellitus [J]. J
Diabetes Res, 2017, 2017: 6719239.
[25]Acetyl-L-carnitine [J]. Altern Med Rev, 1999, 4(6):
438-41.
[26]Li S, Chen X, Li Q, et al. Effects of acetyl-Lcarnitine and methylcobalamin for diabetic peripheral
neuropathy: A multicenter, randomized, double-blind,
controlled trial [J]. J Diabetes Investig, 2016, 7(5): 777-85.
[27]Didangelos T, Karlafti E, Kotzakioulafi E, et al.
Efficacy and Safety of the Combination of Superoxide
Dismutase, Alpha Lipoic Acid, Vitamin B12, and Carnitine
for 12 Months in Patients with Diabetic Neuropathy [J].
Nutrients, 2020, 12(11).
regional diabetes prevalence estimates for 2019 and projections
for 2030 and 2045: Results from the International Diabetes
Federation Diabetes Atlas, 9(th) edition [J]. Diabetes Res Clin
Pract, 2019, 157: 107843.
[2]Elafros MA, Andersen H, Bennett DL, et al. Towards
prevention of diabetic peripheral neuropathy: clinical
presentation, pathogenesis, and new treatments [J]. Lancet
Neurol, 2022, 21(10): 922-36.
[3]Feldman EL, Callaghan BC, Pop-Busui R, et al.
Diabetic neuropathy [J]. Nat Rev Dis Primers, 2019, 5(1): 41.
[4]Sloan G, Selvarajah D, Tesfaye S. Pathogenesis,
diagnosis and clinical management of diabetic sensorimotor
peripheral neuropathy [J]. Nat Rev Endocrinol, 2021, 17(7):
400-20.
[5]Calcutt NA. Diabetic neuropathy and neuropathic
pain: a (con)fusion of pathogenic mechanisms? [J]. Pain, 2020,
161(Suppl 1): S65-s86.
[6]Effect of intensive diabetes treatment on the
development and progression of long-term complications
in adolescents with insulin-dependent diabetes mellitus:
Diabetes Control and Complications Trial. Diabetes Control
and Complications Trial Research Group [J]. J Pediatr, 1994,
125(2): 177-88.
[7]Liu Y, Sayam S, Shao X, et al. Prevalence of and
Trends in Diabetes Among Veterans, United States, 2005-
2014 [J]. Prev Chronic Dis, 2017, 14: E135.
[8]Nisar MU, Asad A, Waqas A, et al. Association of
Diabetic Neuropathy with Duration of Type 2 Diabetes and
Glycemic Control [J]. Cureus, 2015, 7(8): e302.
[9]Ahn S, Song R. Effects of Tai Chi Exercise on
glucose control, neuropathy scores, balance, and quality of life
in patients with type 2 diabetes and neuropathy [J]. J Altern
Complement Med, 2012, 18(12): 1172-8.
[10]Bhrigu B, Sharma S, Kumar N, et al. Assessment
for Diabetic Neuropathy: Treatment and Neurobiological
Perspective [J]. Curr Diabetes Rev, 2025, 21(6): 12-31.
[11]Sawangjit R, Thongphui S, Chaichompu W,
et al. Efficacy and Safety of Mecobalamin on Peripheral
Neuropathy: A Systematic Review and Meta-Analysis of
Randomized Controlled Trials [J]. J Altern Complement
Med, 2020, 26(12): 1117-29.
[12]Miyashita A, Kobayashi M, Yokota T, et al. Diabetic
Polyneuropathy: New Strategies to Target Sensory Neurons
in Dorsal Root Ganglia [J]. Int J Mol Sci, 2023, 24(6).
[13]Himeno T, Kamiya H, Naruse K, et al. Beneficial
effects of exendin-4 on experimental polyneuropathy in
diabetic mice [J]. Diabetes, 2011, 60(9): 2397-406.
[14]Wegeberg AL, Hansen CS, Farmer AD, et al.
Liraglutide accelerates colonic transit in people with type 1
diabetes and polyneuropathy: A randomised, double-blind,
placebo-controlled trial [J]. United European Gastroenterol J,
2020, 8(6): 695-704.
[15]Brock C, Hansen CS, Karmisholt J, et al. Liraglutide
treatment reduced interleukin-6 in adults with type 1 diabetes
but did not improve established autonomic or polyneuropathy
[J]. Br J Clin Pharmacol, 2019, 85(11): 2512-23.
[16]Ziegler D, Low PA, Litchy WJ, et al. Efficacy and
safety of antioxidant treatment with α-lipoic acid over 4
years in diabetic polyneuropathy: the NATHAN 1 trial [J].
Diabetes Care, 2011, 34(9): 2054-60.
[17]Mijnhout GS, Kollen BJ, Alkhalaf A, et al. Alpha
lipoic Acid for symptomatic peripheral neuropathy in patients
with diabetes: a meta-analysis of randomized controlled trials
[J]. Int J Endocrinol, 2012, 2012: 456279.
[18]Sato K, Tatsunami R, Wakame K. Epalrestat
suppresses inflammatory response in lipopolysaccharide-
Refbacks
- 当前没有refback。
